タバコを止めるだけでセカンドカーをゲット出来ました！ってお話…
2014年09月25日
ちょっと興味深いお話を・・・
先月、弊社のアルファロメオGTAをご購入いただきました
お客様のお話・・・
ご主人様がご自分の趣味のクルマということで
現金でも購入できるのですが
なにか、この購入にあたっての
「買う、きっかけが欲しい・・・」
これをきっかけに、タバコをやめてしまおうか？
・・・と、ご契約の日からお見事に
タバコをやめられました！
ご家族の車も、このアルファロメオ１４７GTAを買うと
３台となり・・・
現金でも買えるのだが、自分の専用趣味クルマとしては
このご時世、なんとなく贅沢な感じで買い辛い・・・
きっと、クルマ好きの方はそんな思いを感じられたことが有るのでは・・・？
自分専用趣味クルマとして買うには
どうにか、±０で買えないものか・・・
たばこをやめて・・・趣味クルマと健康が買えた！
一石二鳥ってこのことなんでしょうか。
「クルマを買いたいから、たばこをやめる・・・」
なんとなく、しみじみ・・・さめてしまう感じ。
なら、発想の逆転で
「たばこを止めたいから、クルマを買う」
しかも、自分専用機の贅沢な趣味クルマをだ。
趣味クルマだからこそ、この発想は成り立つようだ。
ハイブリッドなエコ実用車を買ってしまうと
その浮いたお金で、タバコが買えてしまうからだ・・・
休みの日に、スパイスいっぱい詰め込んだ
贅沢な趣味クルマを触って乗って眺めて味わって・・・
しかも、タバコを止める口実も出来て
百害あって一利なし、一番大切な自分自身の健康もいっしょに
「クルマと健康を引き寄せられるのです。」
１００万円前後くらいの価格が買いやすい。
タバコを止める口実には
あまり、安すぎる買い物のきっかけではまたぶり返すかもしれないし、
高すぎても現実的には難しい。
ちょっと、計算してみたらおもしろかったので・・・
たばこの値段、一箱460円として
460円×30日＝13,800円
一箱吸う人で、月々13,800円も必要なんですね。
二箱なら、27,600円！ひぇー。
ウケてます。新型オートローン。
「自由返済型低金利オートローン。」
オートローンなのに、
自分の勝手で、
支払期間を延ばしたり、縮めたり、
増やしたり、減らしたり・・・
ちょっと、お金が余ったので、スポット返済できたり、
予期せぬ出費で、今月の支払いは無しにできたり。
「月々の支払い金額も、支払回数も、自由に決められる新ローン」
でも、この手のローンは金利が高いんじゃないの？って思いませんか？
弊社では、昔からの従来型の固定支払いローンの金利と同じ低金利で
ご利用可能になりました。
とてもお手軽で、柔軟に対応できるローンになりましたので
たいへんおススメだと思います。
こんな、便利なローンをご利用いただけるようになりましたので、
今回のテーマ
「タバコを止めるだけでセカンドカーをゲット出来ました！」
を、この自由返済型ローンのお支払でシュミレーションしてみました。
アルファロメオ
９１６スパイダー電動トップ 趣味的クルマ（綺麗ですヨ！）
トイカーランド価格：670,000円税込 （安くて程度いいです）
検査２年種取得して、自動車税や重量税、自賠責保険も加入して
納車前点検整備を実施しまして、
（弊社サービス、ヴァレンテリアでバッチリ！）
登録、ご納車までの費用をたしての総額：851,820円
頭金も０円で計算をしてみました。
タバコ
460円×30日＝13,800円
月々、13,800円として
毎月の支払いを、13,800円の支払金額でオールローンで試算してみると・・・
ローン元金 851,820円
頭金 0円
毎月、13,800円×69回
47円最終回（70回）
っと、７０回払いの計算になる。
70回目は、47円だけ。
70回って、永遠って感じ？
でも、70回もタバコをやめる口実ができるワケです。
７０回も健康なワケですね。
でも、ローンの途中でなんかあったら困るかも・・・
こんなとき、自由返済型ローンが有効になったり・・・
スポット的にちょっと入れて、
回数も減らせることができたり
支払金額を減らしたりもできるので便利なのです・・・
ちなみに、このローン。支払回数が最長96回まで可能なのです。
なので、とりあえず永く時々スポットで返したり
自由返済型なので、途中で回数を少なくすることも可能だ。
タバコをやめる口実に、
７０月（5年ちょっと）今より健康でいられて
さらに、趣味のクルマもついてくるのだ。
一石二鳥の、趣味クルマ購入口実創り。
健康も入手できて、クルマで癒されて・・・
やっぱ、こだわりの輸入車っていいな。
FIAT 最終バルケッタ ジョーヴァネ ドゥーエ
トイカーランド価格 690,000円税込
こんなのも、人気でご来店いただいております。
癒し趣味的セカンドカーに最適？な価格だと思いませんか？
タバコをやめて、セカンドカーをゲット！お見積りの請求はコチラ
在庫不足なので少しだけございます。
トイカーランドは
なぜかたまたま、ほとんどタバコを吸わないスタッフばかりですが
「百薬の長」ってな
お酒だけはやめられへんしー
この記事へのコメント
(Kristy)
Oxandrolone: Side Effects, Uses, Dosage, Interactions, Warnings
**Common Side Effects of Selective Serotonin Reuptake Inhibitors (SSRIs)**
(Examples: sertraline, fluoxetine, paroxetine, escitalopram,
citalopram)
| System / Category | Typical Symptoms |
|-------------------|------------------|
| **Gastrointestinal** | Nausea, vomiting, diarrhea, constipation, abdominal discomfort |
| **Central Nervous System** | Headache, dizziness, insomnia or drowsiness, anxiety,
agitation, restlessness |
| **Sexual Function** | Decreased libido, delayed orgasm
or anorgasmia, erectile dysfunction, reduced arousal
|
| **Neuromuscular** | Muscle aches or stiffness, tremor, tingling (paresthesias) |
| **Cardiovascular** | Palpitations, mild tachycardia; rarely bradycardia or
arrhythmias in susceptible individuals |
| **Metabolic** | Weight gain or loss, changes in appetite; rare
hypoglycemia in predisposed patients |
These side?effects reflect the pharmacodynamics of serotonin reuptake inhibition and are typically dose?related.
Most resolve with adjustment of dose, discontinuation,
or time.
---
## 2. Drugs that Reduce the Effectiveness of Serotonin Antidepressants
### A. Medications Increasing CYP450 Metabolism (Enzymatic
Inducers)
| Drug | Enzyme Induced | Clinical Impact on SSRIs / SNRIs
|
|------|----------------|----------------------------------|
| **Carbamazepine** | CYP3A4, CYP2C9, CYP1A2 | ↑ metabolism → ↓ plasma SSRI/SNRI levels (e.g.,
sertraline, fluoxetine). Can lead to sub?therapeutic
effect. |
| **Phenobarbital** | CYP3A4, CYP2B6 | Similar reduction in SSRI exposure; risk of treatment failure.
|
| **Phenytoin** | CYP2C9, CYP3A4 | Reduces sertraline/fluoxetine levels.
|
| **Valproic acid** (high doses) | Induces CYP enzymes | Can lower SSRI concentrations; monitor for loss of efficacy.
|
| **Isoniazid + Rifampicin** | Rifampicin induces CYP1A2, 3A4 | Dramatically decreases fluvoxamine/fluoxetine
levels. |
These drugs may be used in comorbid conditions (e.g., epilepsy, tuberculosis).
When combined with SSRIs, clinicians must monitor for loss of antidepressant effect or adjust SSRI dose upward.
---
## 5. Clinical Recommendations & Practical Tips
| Scenario | Key Actions |
|----------|-------------|
| **Starting an SSRI** | - Review all current meds (OTC, supplements).
- Check for interactions with CYP2D6 inhibitors/inducers.
- Counsel patient on potential GI upset; consider taking with food or using a prodrug (e.g., fluoxetine).
|
| **Adding a new drug** | - If the new drug is
a CYP2D6 inhibitor (e.g., paroxetine, fluoxetine), anticipate increased SSRI levels
→ monitor for side?effects.
- If the new drug is an inducer (e.g., carbamazepine), consider dose adjustment of SSRI.
|
| **Changing dose** | - For medications that alter CYP activity,
adjust SSRI dose accordingly: lower dose if induction; consider
tapering if inhibition causes high levels. |
| **Switching SSRIs** | - When switching due to side?effects or drug interactions, account for differing metabolic pathways (e.g., citalopram less reliant on CYP2D6).
|
| **Monitoring** | - Watch for signs of serotonin syndrome especially when combining with other serotonergic agents (MAO
inhibitors, tramadol, etc.). |
---
## 4. Practical Management Flowchart
```
Start
│
▼
Assess current meds: Identify any CYP inhibitors/inducers.
│
▼
If inhibitor present:
├─ Evaluate SSRIs’ metabolism
└─ Consider dose reduction or switch to less metabolized SSRI
(e.g., citalopram, sertraline)
If inducer present:
├─ Assess risk of sub?therapeutic SSRI levels
└─ Increase SSRI dose cautiously; monitor for efficacy
and side effects
Check for concurrent MAO?I or serotonergic drugs.
│
├─ If yes → Discontinue SSRI or MAO?I, ensure adequate washout period (?14 days)
└─ Else continue monitoring
Monitor patient:
- Adverse effects: Hyponatremia, serotonin syndrome signs
- Efficacy: Depression scales
- Labs: Serum sodium if hyponatremic symptoms; TSH if hypothyroid risk
Adjust treatment accordingly.
```
**Key points**
* **Drug?drug interactions** ? avoid combining serotonergic drugs
(SSRIs with MAO?I, other SSRIs, TCAs, SNRIs, tramadol, linezolid) unless clinically justified and with appropriate
washout periods.
* **Side?effect monitoring** ? hyponatremia is a notable
risk in older adults; screen for neurological signs of serotonin syndrome (agitation, clonus, hyperreflexia).
* **Patient?specific factors** ? consider comorbidities such as hypothyroidism, renal dysfunction, or cardiovascular disease when choosing an SSRI.
---
## 3. Recommendations for the patient’s current
medication regimen
| Current Medication | Role in treatment
| Potential interactions / cautions |
|--------------------|-------------------|-----------------------------------|
| **Citalopram** | Primary antidepressant; evidence base in older adults, especially with comorbid conditions such
as hypertension and osteoarthritis. | ? Monitor QT interval (especially if
other QT?prolonging drugs are added).
? Dose adjustment if renal impairment present.
? Watch for orthostatic hypotension when combined with antihypertensives.
|
| **Paroxetine** | May still be used if anxiety or insomnia predominates, but
less favorable due to CYP2D6 inhibition and higher anticholinergic burden. | ?
Consider switching away from paroxetine to reduce
cognitive side effects.
? Evaluate need for benzodiazepines (e.g., lorazepam) carefully?avoid
long?term use. |
| **Lorazepam** | Useful short?term anxiolytic;
avoid chronic dependence.
**Alternative**: consider low?dose **clonazepam** if
needed, but still cautious. |
| **Clonazepam** | If used, limit to 2?3 weeks and then taper off due to risk
of dependence. |
---
## 4. Practical Prescription Plan
### 1. Pain Management (General)
| Medication | Dose/Regimen | Notes |
|------------|--------------|-------|
| **Acetaminophen 500 mg** | PO q6h PRN (max 4000 mg/day)
| First?line for mild to moderate pain. |
| **Ibuprofen 200 mg** | PO q6?8h PRN (max 1200 mg/day) | For
inflammatory pain; avoid if GI, renal, or hepatic disease present.
|
| **Diclofenac sodium 50 mg** | PO q12h | Alternative
NSAID; monitor for GI bleeding. |
### If NSAIDs Contraindicated:
| Med | Dose | Notes |
|-----|------|-------|
| **Gabapentin 100 mg** | PO q8h PRN (max 1800 mg/day) |
For neuropathic pain. |
| **Clonazepam 0.5 mg** | PO q12h PRN | Short?term anxiolytic; avoid long?term use due to
dependence risk. |
---
## 3. Pain Management & Medication Safety
### Key Points for Managing Elderly Patients
1. **Start Low, Go Slow**
* Use the lowest effective dose of analgesics (e.g., opioids) and titrate
slowly.
2. **Avoid Polypharmacy Risks**
* Screen for drug?drug interactions (especially with
CYP3A4 inhibitors/inducers).
* Avoid "red flag" combinations such as opioid + benzodiazepine or strong CNS depressants.
3. **Monitor Renal & Hepatic Function**
* Adjust dosing of drugs eliminated renally (e.g., tramadol, methadone) or hepatically (e.g.,
fentanyl).
4. **Use Non?Opioid Alternatives First**
* NSAIDs if renal function permits; acetaminophen (avoid >3?g/day).
* Adjuvants: gabapentinoids (gabapentin, pregabalin), duloxetine, amitriptyline (low
dose).
5. **Regular Re?assessment of Pain Scores**
* Use numeric rating scales or visual analog scales at each visit.
* Adjust treatment if pain increases >20% over baseline.
6. **Monitor for Adverse Effects**
* Sedation, constipation, urinary retention, dizziness, respiratory depression (especially in combination with benzodiazepines).
7. **Non?pharmacologic Support**
* Encourage physical therapy, gentle exercise as tolerated.
* Cognitive behavioral strategies for pain coping.
---
## 5. Summary of Recommended Medication Regimen
| **Medication** | **Dose & Schedule** | **Monitoring / Precautions** |
|-----------------|---------------------|------------------------------|
| **Methadone** (if needed) | Start 10?mg PO q24h → titrate to ~25?30?mg PO q12h; aim for steady?state level 50?80?ng/mL.
| ECG, serum methadone, pain assessment. |
| **Morphine** (alternative) | 15?20?mg PO
q8h PRN; may increase if pain worsens. | Serum morphine, renal function. |
| **Oxycodone** (alternative) | 10?15?mg PO q6?8h PRN; monitor for tolerance and
side effects. | Same as above. |
| **Hydromorphone** (alternative) | 1?2?mg PO q6h PRN; adjust per pain severity.
| Monitor sedation, respiratory rate. |
---
## 4. Multidisciplinary Pain Management Plan
| Discipline | Role & Actions |
|------------|----------------|
| **Pain Physician / Anesthesiologist** | ? Conduct comprehensive pain assessment.
? Adjust opioid regimens, consider adjuvants (gabapentinoids, NMDA
antagonists).
? Evaluate for interventional procedures (cordotomy, nerve blocks).
|
| **Physical Therapist** | ? Develop graded mobilization program to maintain joint ROM and muscle strength.
? Teach energy?conserving techniques.
? Incorporate aquatic therapy if feasible. |
| **Occupational Therapist** | ? Assess functional limitations; provide adaptive equipment for dressing, grooming.
? Recommend strategies to reduce repetitive strain on shoulder (e.g., use of long?handle tools).
|
| **Speech/Language Pathologist** | *Not directly relevant* unless speech is affected by neurologic
deficits. |
| **Neurologist** | *If neurologic deficits are present*: manage
spasticity, monitor for progression; refer to physiatrists
or neurorehabilitation specialists. |
| **Psychologist / Psychiatrist** | Address depression/anxiety, provide cognitive?behavioral therapy to improve coping and adherence to rehab.
|
---
## 5. Rehabilitation & Prevention of Further Disability
### 5.1 Core Rehabilitation Goals
- Maintain/restore shoulder joint mobility.
- Preserve muscle strength (especially rotator cuff and scapular stabilizers).
- Prevent secondary contractures or deformities.
- Educate patient for self?management.
### 5.2 Exercise Prescription
| Phase | Objectives | Example Exercises | Frequency |
|-------|------------|-------------------|-----------|
| **Acute/Subacute (0?4?wk)** | Protect healing tissues, prevent stiffness.
| - Passive shoulder flexion/extension
- Pendulum swings
- Assisted abduction/adduction | 5?10 reps × 2?3 times daily |
| **Early Functional (4?8?wk)** | Increase
ROM, start active movement. | - Active-assisted shoulder flexion/extension
- Shoulder circles
- Wall climbing | 3 sets of 10?15 reps, 3× daily |
| **Mid-Phase (8?12?wk)** | Strengthen rotator
cuff and scapular stabilizers. | - Isometric external/internal rotation
- Scapular retractions
- Resistance band rows | 3 sets of 8?12 reps, 2?3×
weekly |
| **Late Phase (>12?wk)** | Return to functional tasks, improve
endurance. | - Functional drills (e.g., medicine ball
throws)
- Plyometric exercises
- Sport-specific conditioning | Progressive overload, 2?4×
weekly |
#### 1.5 Rehabilitation Progression
| Stage | Time Frame | Goals | Key Interventions |
|-------|------------|-------|-------------------|
| **Acute** | Weeks 0?2 | Protect joint; minimize pain/inflammation;
maintain ROM. | NSAIDs, ice, gentle passive/active-assisted ROM; early quadriceps activation (isometrics).
|
| **Subacute** | Weeks 3?6 | Restore full ROM; begin strength and proprioception. | Full active
ROM; closed kinetic chain exercises; balance boards.
|
| **Reconditioning** | Weeks 7?12 | Maximize strength, endurance, neuromuscular control.
| Plyometrics; sport-specific drills; dynamic stability training.
|
| **Return to Play** | Weeks 13+ | Achieve pre-injury performance
level. | Sport-simulated conditioning; psychological readiness assessment.
|
---
## 5. Clinical Decision-Making Flowchart
```
Patient presents with knee injury
│
▼
Perform Physical Exam & History
│
┌─────────┴───────────────────────┐
│ │
Symptom pattern? Imaging?
│ │
│ ▼
│ X?ray, MRI, Ultrasound
│ │
│ ▼
│ Evaluate for fractures, ACL tear,
│ meniscal tears, osteochondral lesions, etc.
│ │
├─────────────────────┬───────────┘
│ │
Yes (specific findings) No
│ │
▼ ▼
Diagnosis: Fracture, ACL tear,
Meniscal injury, etc. Reassess history; consider less common
conditions (e.g., osteochondritis dissecans)
│ │
▼ ▼
Determine treatment plan:
? Surgical or conservative management as appropriate.
? Address mechanical issues if present (e.g., meniscus repair,
osteotomy, arthroplasty).
└───────────────────────┘
END
```
---
### Clinical Reasoning Flow (Narrative)
1. **History & Physical**
- Start by establishing the mechanism of injury: sudden impact or repetitive micro?trauma?
- Determine whether pain is localized, diffuse, or related to specific motions.
- Assess for swelling, effusion, instability, and range?of?motion deficits.
2. **Differential Based on Mechanism**
- *Impact*: consider ligamentous injuries (ACL,
PCL), meniscal tears, articular cartilage lesions.
- *Repetitive*: look at overuse syndromes such as osteochondritis dissecans, early OA, or chondromalacia patellae.
3. **Examine Physical Findings**
- A positive McMurray test points to a meniscal tear.
- Anterior drawer or Lachman test indicates ACL involvement.
- Positive joint line tenderness may suggest medial compartment OA or
osteochondritis dissecans.
4. **Order Imaging and Tests According to Likelihood**
- MRI for suspected ligamentous or meniscal injury.
- X?ray for OA, alignment problems, or bony
lesions.
- CT if a structural defect like ODG is suspected.
- Arthrography when a subtle intra?articular pathology needs confirmation.
5. **Synthesize Findings**
- Combine history, physical exam, and imaging to identify the most probable lesion (e.g., medial compartment OA).
- Consider alternative diagnoses if findings do not align or new
symptoms appear.
6. **Develop a Plan**
- Decide on conservative treatment, possible injections, or surgical referral based on diagnosis and severity.
By systematically collecting data, evaluating each piece of information, and integrating them logically, you can arrive at the most
accurate clinical decision for each patient.
**Common Side Effects of Selective Serotonin Reuptake Inhibitors (SSRIs)**
(Examples: sertraline, fluoxetine, paroxetine, escitalopram,
citalopram)
| System / Category | Typical Symptoms |
|-------------------|------------------|
| **Gastrointestinal** | Nausea, vomiting, diarrhea, constipation, abdominal discomfort |
| **Central Nervous System** | Headache, dizziness, insomnia or drowsiness, anxiety,
agitation, restlessness |
| **Sexual Function** | Decreased libido, delayed orgasm
or anorgasmia, erectile dysfunction, reduced arousal
|
| **Neuromuscular** | Muscle aches or stiffness, tremor, tingling (paresthesias) |
| **Cardiovascular** | Palpitations, mild tachycardia; rarely bradycardia or
arrhythmias in susceptible individuals |
| **Metabolic** | Weight gain or loss, changes in appetite; rare
hypoglycemia in predisposed patients |
These side?effects reflect the pharmacodynamics of serotonin reuptake inhibition and are typically dose?related.
Most resolve with adjustment of dose, discontinuation,
or time.
---
## 2. Drugs that Reduce the Effectiveness of Serotonin Antidepressants
### A. Medications Increasing CYP450 Metabolism (Enzymatic
Inducers)
| Drug | Enzyme Induced | Clinical Impact on SSRIs / SNRIs
|
|------|----------------|----------------------------------|
| **Carbamazepine** | CYP3A4, CYP2C9, CYP1A2 | ↑ metabolism → ↓ plasma SSRI/SNRI levels (e.g.,
sertraline, fluoxetine). Can lead to sub?therapeutic
effect. |
| **Phenobarbital** | CYP3A4, CYP2B6 | Similar reduction in SSRI exposure; risk of treatment failure.
|
| **Phenytoin** | CYP2C9, CYP3A4 | Reduces sertraline/fluoxetine levels.
|
| **Valproic acid** (high doses) | Induces CYP enzymes | Can lower SSRI concentrations; monitor for loss of efficacy.
|
| **Isoniazid + Rifampicin** | Rifampicin induces CYP1A2, 3A4 | Dramatically decreases fluvoxamine/fluoxetine
levels. |
These drugs may be used in comorbid conditions (e.g., epilepsy, tuberculosis).
When combined with SSRIs, clinicians must monitor for loss of antidepressant effect or adjust SSRI dose upward.
---
## 5. Clinical Recommendations & Practical Tips
| Scenario | Key Actions |
|----------|-------------|
| **Starting an SSRI** | - Review all current meds (OTC, supplements).
- Check for interactions with CYP2D6 inhibitors/inducers.
- Counsel patient on potential GI upset; consider taking with food or using a prodrug (e.g., fluoxetine).
|
| **Adding a new drug** | - If the new drug is
a CYP2D6 inhibitor (e.g., paroxetine, fluoxetine), anticipate increased SSRI levels
→ monitor for side?effects.
- If the new drug is an inducer (e.g., carbamazepine), consider dose adjustment of SSRI.
|
| **Changing dose** | - For medications that alter CYP activity,
adjust SSRI dose accordingly: lower dose if induction; consider
tapering if inhibition causes high levels. |
| **Switching SSRIs** | - When switching due to side?effects or drug interactions, account for differing metabolic pathways (e.g., citalopram less reliant on CYP2D6).
|
| **Monitoring** | - Watch for signs of serotonin syndrome especially when combining with other serotonergic agents (MAO
inhibitors, tramadol, etc.). |
---
## 4. Practical Management Flowchart
```
Start
│
▼
Assess current meds: Identify any CYP inhibitors/inducers.
│
▼
If inhibitor present:
├─ Evaluate SSRIs’ metabolism
└─ Consider dose reduction or switch to less metabolized SSRI
(e.g., citalopram, sertraline)
If inducer present:
├─ Assess risk of sub?therapeutic SSRI levels
└─ Increase SSRI dose cautiously; monitor for efficacy
and side effects
Check for concurrent MAO?I or serotonergic drugs.
│
├─ If yes → Discontinue SSRI or MAO?I, ensure adequate washout period (?14 days)
└─ Else continue monitoring
Monitor patient:
- Adverse effects: Hyponatremia, serotonin syndrome signs
- Efficacy: Depression scales
- Labs: Serum sodium if hyponatremic symptoms; TSH if hypothyroid risk
Adjust treatment accordingly.
```
**Key points**
* **Drug?drug interactions** ? avoid combining serotonergic drugs
(SSRIs with MAO?I, other SSRIs, TCAs, SNRIs, tramadol, linezolid) unless clinically justified and with appropriate
washout periods.
* **Side?effect monitoring** ? hyponatremia is a notable
risk in older adults; screen for neurological signs of serotonin syndrome (agitation, clonus, hyperreflexia).
* **Patient?specific factors** ? consider comorbidities such as hypothyroidism, renal dysfunction, or cardiovascular disease when choosing an SSRI.
---
## 3. Recommendations for the patient’s current
medication regimen
| Current Medication | Role in treatment
| Potential interactions / cautions |
|--------------------|-------------------|-----------------------------------|
| **Citalopram** | Primary antidepressant; evidence base in older adults, especially with comorbid conditions such
as hypertension and osteoarthritis. | ? Monitor QT interval (especially if
other QT?prolonging drugs are added).
? Dose adjustment if renal impairment present.
? Watch for orthostatic hypotension when combined with antihypertensives.
|
| **Paroxetine** | May still be used if anxiety or insomnia predominates, but
less favorable due to CYP2D6 inhibition and higher anticholinergic burden. | ?
Consider switching away from paroxetine to reduce
cognitive side effects.
? Evaluate need for benzodiazepines (e.g., lorazepam) carefully?avoid
long?term use. |
| **Lorazepam** | Useful short?term anxiolytic;
avoid chronic dependence.
**Alternative**: consider low?dose **clonazepam** if
needed, but still cautious. |
| **Clonazepam** | If used, limit to 2?3 weeks and then taper off due to risk
of dependence. |
---
## 4. Practical Prescription Plan
### 1. Pain Management (General)
| Medication | Dose/Regimen | Notes |
|------------|--------------|-------|
| **Acetaminophen 500 mg** | PO q6h PRN (max 4000 mg/day)
| First?line for mild to moderate pain. |
| **Ibuprofen 200 mg** | PO q6?8h PRN (max 1200 mg/day) | For
inflammatory pain; avoid if GI, renal, or hepatic disease present.
|
| **Diclofenac sodium 50 mg** | PO q12h | Alternative
NSAID; monitor for GI bleeding. |
### If NSAIDs Contraindicated:
| Med | Dose | Notes |
|-----|------|-------|
| **Gabapentin 100 mg** | PO q8h PRN (max 1800 mg/day) |
For neuropathic pain. |
| **Clonazepam 0.5 mg** | PO q12h PRN | Short?term anxiolytic; avoid long?term use due to
dependence risk. |
---
## 3. Pain Management & Medication Safety
### Key Points for Managing Elderly Patients
1. **Start Low, Go Slow**
* Use the lowest effective dose of analgesics (e.g., opioids) and titrate
slowly.
2. **Avoid Polypharmacy Risks**
* Screen for drug?drug interactions (especially with
CYP3A4 inhibitors/inducers).
* Avoid "red flag" combinations such as opioid + benzodiazepine or strong CNS depressants.
3. **Monitor Renal & Hepatic Function**
* Adjust dosing of drugs eliminated renally (e.g., tramadol, methadone) or hepatically (e.g.,
fentanyl).
4. **Use Non?Opioid Alternatives First**
* NSAIDs if renal function permits; acetaminophen (avoid >3?g/day).
* Adjuvants: gabapentinoids (gabapentin, pregabalin), duloxetine, amitriptyline (low
dose).
5. **Regular Re?assessment of Pain Scores**
* Use numeric rating scales or visual analog scales at each visit.
* Adjust treatment if pain increases >20% over baseline.
6. **Monitor for Adverse Effects**
* Sedation, constipation, urinary retention, dizziness, respiratory depression (especially in combination with benzodiazepines).
7. **Non?pharmacologic Support**
* Encourage physical therapy, gentle exercise as tolerated.
* Cognitive behavioral strategies for pain coping.
---
## 5. Summary of Recommended Medication Regimen
| **Medication** | **Dose & Schedule** | **Monitoring / Precautions** |
|-----------------|---------------------|------------------------------|
| **Methadone** (if needed) | Start 10?mg PO q24h → titrate to ~25?30?mg PO q12h; aim for steady?state level 50?80?ng/mL.
| ECG, serum methadone, pain assessment. |
| **Morphine** (alternative) | 15?20?mg PO
q8h PRN; may increase if pain worsens. | Serum morphine, renal function. |
| **Oxycodone** (alternative) | 10?15?mg PO q6?8h PRN; monitor for tolerance and
side effects. | Same as above. |
| **Hydromorphone** (alternative) | 1?2?mg PO q6h PRN; adjust per pain severity.
| Monitor sedation, respiratory rate. |
---
## 4. Multidisciplinary Pain Management Plan
| Discipline | Role & Actions |
|------------|----------------|
| **Pain Physician / Anesthesiologist** | ? Conduct comprehensive pain assessment.
? Adjust opioid regimens, consider adjuvants (gabapentinoids, NMDA
antagonists).
? Evaluate for interventional procedures (cordotomy, nerve blocks).
|
| **Physical Therapist** | ? Develop graded mobilization program to maintain joint ROM and muscle strength.
? Teach energy?conserving techniques.
? Incorporate aquatic therapy if feasible. |
| **Occupational Therapist** | ? Assess functional limitations; provide adaptive equipment for dressing, grooming.
? Recommend strategies to reduce repetitive strain on shoulder (e.g., use of long?handle tools).
|
| **Speech/Language Pathologist** | *Not directly relevant* unless speech is affected by neurologic
deficits. |
| **Neurologist** | *If neurologic deficits are present*: manage
spasticity, monitor for progression; refer to physiatrists
or neurorehabilitation specialists. |
| **Psychologist / Psychiatrist** | Address depression/anxiety, provide cognitive?behavioral therapy to improve coping and adherence to rehab.
|
---
## 5. Rehabilitation & Prevention of Further Disability
### 5.1 Core Rehabilitation Goals
- Maintain/restore shoulder joint mobility.
- Preserve muscle strength (especially rotator cuff and scapular stabilizers).
- Prevent secondary contractures or deformities.
- Educate patient for self?management.
### 5.2 Exercise Prescription
| Phase | Objectives | Example Exercises | Frequency |
|-------|------------|-------------------|-----------|
| **Acute/Subacute (0?4?wk)** | Protect healing tissues, prevent stiffness.
| - Passive shoulder flexion/extension
- Pendulum swings
- Assisted abduction/adduction | 5?10 reps × 2?3 times daily |
| **Early Functional (4?8?wk)** | Increase
ROM, start active movement. | - Active-assisted shoulder flexion/extension
- Shoulder circles
- Wall climbing | 3 sets of 10?15 reps, 3× daily |
| **Mid-Phase (8?12?wk)** | Strengthen rotator
cuff and scapular stabilizers. | - Isometric external/internal rotation
- Scapular retractions
- Resistance band rows | 3 sets of 8?12 reps, 2?3×
weekly |
| **Late Phase (>12?wk)** | Return to functional tasks, improve
endurance. | - Functional drills (e.g., medicine ball
throws)
- Plyometric exercises
- Sport-specific conditioning | Progressive overload, 2?4×
weekly |
#### 1.5 Rehabilitation Progression
| Stage | Time Frame | Goals | Key Interventions |
|-------|------------|-------|-------------------|
| **Acute** | Weeks 0?2 | Protect joint; minimize pain/inflammation;
maintain ROM. | NSAIDs, ice, gentle passive/active-assisted ROM; early quadriceps activation (isometrics).
|
| **Subacute** | Weeks 3?6 | Restore full ROM; begin strength and proprioception. | Full active
ROM; closed kinetic chain exercises; balance boards.
|
| **Reconditioning** | Weeks 7?12 | Maximize strength, endurance, neuromuscular control.
| Plyometrics; sport-specific drills; dynamic stability training.
|
| **Return to Play** | Weeks 13+ | Achieve pre-injury performance
level. | Sport-simulated conditioning; psychological readiness assessment.
|
---
## 5. Clinical Decision-Making Flowchart
```
Patient presents with knee injury
│
▼
Perform Physical Exam & History
│
┌─────────┴───────────────────────┐
│ │
Symptom pattern? Imaging?
│ │
│ ▼
│ X?ray, MRI, Ultrasound
│ │
│ ▼
│ Evaluate for fractures, ACL tear,
│ meniscal tears, osteochondral lesions, etc.
│ │
├─────────────────────┬───────────┘
│ │
Yes (specific findings) No
│ │
▼ ▼
Diagnosis: Fracture, ACL tear,
Meniscal injury, etc. Reassess history; consider less common
conditions (e.g., osteochondritis dissecans)
│ │
▼ ▼
Determine treatment plan:
? Surgical or conservative management as appropriate.
? Address mechanical issues if present (e.g., meniscus repair,
osteotomy, arthroplasty).
└───────────────────────┘
END
```
---
### Clinical Reasoning Flow (Narrative)
1. **History & Physical**
- Start by establishing the mechanism of injury: sudden impact or repetitive micro?trauma?
- Determine whether pain is localized, diffuse, or related to specific motions.
- Assess for swelling, effusion, instability, and range?of?motion deficits.
2. **Differential Based on Mechanism**
- *Impact*: consider ligamentous injuries (ACL,
PCL), meniscal tears, articular cartilage lesions.
- *Repetitive*: look at overuse syndromes such as osteochondritis dissecans, early OA, or chondromalacia patellae.
3. **Examine Physical Findings**
- A positive McMurray test points to a meniscal tear.
- Anterior drawer or Lachman test indicates ACL involvement.
- Positive joint line tenderness may suggest medial compartment OA or
osteochondritis dissecans.
4. **Order Imaging and Tests According to Likelihood**
- MRI for suspected ligamentous or meniscal injury.
- X?ray for OA, alignment problems, or bony
lesions.
- CT if a structural defect like ODG is suspected.
- Arthrography when a subtle intra?articular pathology needs confirmation.
5. **Synthesize Findings**
- Combine history, physical exam, and imaging to identify the most probable lesion (e.g., medial compartment OA).
- Consider alternative diagnoses if findings do not align or new
symptoms appear.
6. **Develop a Plan**
- Decide on conservative treatment, possible injections, or surgical referral based on diagnosis and severity.
By systematically collecting data, evaluating each piece of information, and integrating them logically, you can arrive at the most
accurate clinical decision for each patient.
[2025-09-26 01:32:36.51468]
URL
(Stephaine)
Эра выживания скачать торрент в хорошем качестве hd 1080 Эра Выживания
Смотреть Онлайн Бесплатно В Хорошем Качестве 1080
Hd
Смотреть Онлайн Бесплатно В Хорошем Качестве 1080
Hd
[2022-09-30 18:32:32.419404]
URL
(Jason)
Игра на выживание 2 сезон дата выхода серий на ТНТ Игра
На Выживание 2 Сезон 1 2 3 4
5 6 7 8 9 10 11 12 Серия Все Серии Смотреть Онлайн В Хорошем Качестве
На Выживание 2 Сезон 1 2 3 4
5 6 7 8 9 10 11 12 Серия Все Серии Смотреть Онлайн В Хорошем Качестве
[2022-09-30 06:45:32.529725]
URL
(Johanna)
Быстрее пули бесплатно смотреть онлайн Быстрее Пули
Смотреть Онлайн Бесплатно
Смотреть Онлайн Бесплатно
[2022-09-29 05:30:49.307767]
URL
